(A) Expanded access clinical trials conducted pursuant to a statewide investigational new drug application established pursuant to this chapter only shall utilize cannabidiol which is:
- (1) from an approved source; and
- (2) approved by the United States Food and Drug Administration to be used for treatment of a condition specified in an investigational new drug application.
- (B) The principal investigator and any subinvestigator may receive cannabidiol directly from an approved source or authorized distributor for an approved source for use in the expanded access clinical trials.
HISTORY: 2014 Act No. 221 (S.1035), Section 2, eff June 2, 2014.